How Concerning Is Pfizer and Opko's Latest FDA Rejection?

The U.S. Food and Drug Administration (FDA) recently refused to approve Pfizer's (NYSE: PFE) and Opko Health's (NASDAQ: OPK) growth hormone therapy, somatrogon. In this Motley Fool Live video, recorded on Jan. 26, Motley Fool contributors Keith Speights and Brian Orelli discuss how concerning this rejection is for the two companies.